Edition:
United Kingdom

Manas Mishra

Abbott CEO Miles White to step down next year

13 Nov 2019

Abbott Laboratories longtime Chief Executive Officer Miles White will step down in favour of his chief of operations in March, handing over the reins after successfully reshaping the healthcare conglomerate in a series of transformative deals.

Celgene's drug for anemia in beta thalassemia priced at $3,441/ 25 mg vial

08 Nov 2019

Celgene Corp's treatment for anemia in patients with beta thalassemia, a rare blood disorder, would be priced at $3,441 for a 25-milligram vial of the drug, partner Acceleron Pharma Inc said.

CVS quarterly profit beats expectations; shares rise as it eyes growth

06 Nov 2019

CVS Health Corp reported higher-than-expected third-quarter profit on Wednesday as medical costs in its Aetna health insurance business came in below forecasts, and the company said its new strategy of using in-pharmacy clinics would contain healthcare spending going forward.

Eylea powers Regeneron's third-quarter profit beat; shares rise

05 Nov 2019

Drugmaker Regeneron Pharmaceuticals Inc beat analysts' estimates for third-quarter profit on Tuesday, boosted by higher demand for its blockbuster eye drug, Eylea, and eczema therapy Dupixent.

U.S. FDA approves RedHill's bacterial infection treatment

04 Nov 2019

RedHill Biopharma Ltd's said on Monday its three-drug combination therapy to treat Helicobacter pylori bacterial infections had been approved by the U.S. Food and Drug Administration, sending its shares up 25%.

Regular exercise before breast cancer tied to lower heart risk after treatment

31 Oct 2019

(Reuters Health) - Older breast cancer patients who exercised regularly before their cancer diagnosis may be better protected from the heart-harming effects of cancer treatment, a large U.S. study suggests.

Altria writes down Juul investment by $4.5 billion amid vaping backlash

31 Oct 2019

Altria Inc took a $4.5 billion hit from its investment in embattled electronic-cigarette maker Juul Labs Inc on Thursday, the latest setback for the startup as a regulatory crackdown on vaping threatens to upend the fast-growing industry. | Video

Merck sees ongoing Keytruda strength as its sales top $3 billion in quarter

29 Oct 2019

Merck & Co Inc on Tuesday said it expected immunotherapy Keytruda to continue its market dominance as an initial treatment for advanced lung cancer as sales of the drug topped $3 billion (£2.3 billion) in a quarter for the first time, beating lofty Wall Street estimates.

World News